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Abstract
Alzheimer's disease (AD) is one of the most devastating neurodegenerative diseases. It has been known for
decades that the APOE ɛ4 allele is the most significant genetic risk factor for late-onset AD and yet its precise
role in the disease remains unclear. The APOE gene encodes apolipoprotein E (apoE), a 35 kDa glycoprotein
highly expressed in the brain. There are three different isoforms: apoE3 is the most common allele in the
population, whilst apoE2 decreases, and apoE4 increases AD risk. ApoE has numerous functions that affect
neuronal and non-neuronal cells, thus how it contributes to disease onset and progression is hotly debated.
The apoE4 isoform has been linked to the accumulation of both of the major pathological hallmarks of AD,
amyloid plaques containing amyloid β peptides, and neurofibrillary tangles containing hyperphosphorylated
tau protein, as well as other hallmarks of the disease, including inflammation and oxidative stress. Numerous
studies have shown that apoE undergoes fragmentation in the human brain, and that the fragmentation
pattern varies between isoforms. It was previously shown that apoE4 has neurotoxic functions, however recent
data has also identified a neuroprotective role for the apoE N-terminal 25 kDa fragment, which is more
prevalent in apoE3 individuals. The ability of the apoE 25 kDa fragment to promote neurite outgrowth was
recently demonstrated and this suggests there is a potential loss of neuroprotection in apoE4 individuals in
addition to the previously described gain of toxic function for specific apoE4 fragments. Here we review the
enzymes proposed to be responsible for apoE fragmentation, the specific functions of different apoE
fragments and their possible links with AD.
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Abstract 
Alzheimer’s disease (AD) is one of the most devastating neurodegenerative diseases. It has been 
known for decades that the APOE ɛ4 allele is the most significant genetic risk factor for late-onset AD 
and yet its precise role in the disease remains unclear. The APOE gene encodes apolipoprotein E 
(apoE), a 35 kDa glycoprotein highly expressed in the brain. There are three different isoforms: apoE3 
is the most common allele in the population, whilst apoE2 decreases, and apoE4 increases AD risk. 
ApoE has numerous functions that affect neuronal and non-neuronal cells, thus how it contributes to 
disease onset and progression is hotly debated. The apoE4 isoform has been linked to the 
accumulation of both of the major hallmarks of AD, amyloid β (Aβ) plaques and neurofibrillary 
tangles (NFT), as well as other hallmarks of the disease, including inflammation and oxidative stress. 
Numerous studies have shown that apoE undergoes fragmentation in the human brain, and that the 
fragmentation pattern varies between isoforms. It was previously considered that apoE4 has 
neurotoxic functions, however recent data has identified a neuroprotective role for the apoE N-
terminal 25 kDa fragment, which is more prevalent in apoE3 individuals. The ability of the apoE 25 
kDa fragment to promote neurite outgrowth was recently demonstrated and this suggests there is a 
potential loss of neuroprotection in apoE4 individuals. Here we review the enzymes proposed to be 
responsible for apoE fragmentation, the specific functions of different apoE fragments and their 
possible links with AD. 
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Introduction 
Apolipoprotein E (apoE) is a 35-kDa glycoprotein widely expressed in the human body that functions 
as a lipid transporter. Three different alleles of the APOE gene are present in the population: ɛ2, ɛ3 
and ɛ4 , with frequencies of 6.4, 78.3 and 14.5%, respectively [1].  The ɛ4 allele is the major genetic 
risk factor of late-onset AD, whilst ɛ2 protects against the disease [2]. The mechanisms by which 
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APOE genotype influence AD onset and progression are incompletely understood. In the brain, apoE 
is an extracellular protein that is expressed primarily by astrocytes and taken up by neurons; however, 
under certain circumstances, apoE can also be expressed by microglia and neurons [3–5]. ApoE plays 
a major role in the transport of cholesterol and other lipids, participating in their redistribution to cells 
and facilitating their cellular uptake [5]. Moreover, in the brain apoE promotes Aβ clearance and 
neuronal signalling [6]. 
ApoE structure and isoforms 
The domain structure of apoE is composed of two main domains, with the N- and C-terminus, linked 
by a hinge region (Fig. 1)  [7, 8]. The N-terminal domain (residues 1-167) consists of a four alpha-
helix bundle with a region enriched in arginine and lysine residues (135-150) that forms the LDL-
receptor binding region. The C-terminal domain (residues 206-299) consists of amphipathic alpha-
helices characteristic of the apolipoprotein family [9] and includes the lipid binding region (residues 
244-272). 
The three major alleles of the APOE gene found in the population give rise to six different genotypes: 
the homozygotes ε2/2, ε3/3 and ε4/4, and the heterozygotes ε2/3, ε2/4 and ε3/4. The difference 
between the three alleles is only two nucleotides, resulting in a protein change of two amino acids 
located in positions 112 and 158. As shown in Fig., apoE2 contains  Cys
112
 and Cys
158
, apoE3 Cys
112
 
and Arg
158
 and apoE4 Arg
112
 and Arg
158 
[10]. This amino acid change within the isoforms leads to 
differences in protein stability and interactions: by changing Cys
112 
into Arg
112
 in apoE4, the protein 
loses the ionic association between Glu
109
 and Arg
61
, leaving Arg
61
 free to interact with Glu
255
, and 
therefore creating an inter-domain interaction that reduces the lipid binding capacity of apoE4. In 
apoE3 and apoE4 there is a salt-bridge between Arg
158
 and Asparagine (Asp)
154
 that is lost in apoE2 
with Cys
158
. In this case there is a salt-bridge between Asp
154
 and Arg
150
 that removes the positive side 
chain of Arg
150
 away from the LDL receptor binding region, affecting its binding capacity [11]. Due 
to these amino acid interactions, the protein stability differs, with the apoE4 isoform the least stable, 
followed by apoE3, while apoE2 is the most stable [12]. 
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The APOE ɛ4 allele is the major genetic risk factor of Alzheimer’s disease  
The ɛ4 allele of the APOE gene is the major genetic risk factor of late onset AD [2]. Carriers of one 
copy of the APOE ɛ4 are three times more likely to develop AD, and those that are homozygous for 
the APOE ɛ4 have a ten times increased risk of developing the disease [13]. Moreover, the age of 
onset is lower in the APOE ɛ4 AD population [13]. The exact mechanism by which apoE influences 
AD remains unclear. Two of the major hallmarks of AD are the presence of extracellular deposition of 
Aβ, forming amyloid plaques, and the intracellular presence of NFT, composed of aggregations of 
hyperphosphorylated tau protein [14–17].  
One hypothesis linking apoE and AD involves a direct interaction between apoE and Aβ peptides. 
ApoE has been identified within Aβ plaques found in AD brains [18, 19], and other studies in vitro 
have shown that the binding between apoE and Aβ occurs between residues 13-17 of the Aβ peptide 
with residues 144-148 of the N-terminal region and residues 244-248 of the C-terminal region of apoE 
[20, 21]. However, another in vitro study detected minimal levels of interaction between apoE and Aβ 
using the physiological levels found in cerebrospinal fluid (Aβ:apoE molar ratio of 1:50-75), and 
proposed instead that apoE influences Aβ metabolism via interaction with other transporters and 
receptors in cells [22]. ApoE knock-out studies in mice have shown that apoE is necessary to initiate 
and maintain Aβ plaques [23, 24], while another study reported that apoE decreases the initiation of 
Aβ fibril formation [25]. Moreover, apoE4 has been shown to be less effective in the inhibition of Aβ 
fibril formation than apoE3 [25, 26]. Even if the exact mechanism by which apoE interacts with Aβ 
remains to be clarified, microglia could be a central player in mediating this interaction. Microglia 
upregulate apoE under certain stress conditions, and they have been found surrounding Aβ plaques 
[27]. Moreover, a recent study showed that apoE deficiency in mice reduced microglial activation 
around Aβ plaques [28], which could result in a reduced ability to clear Aβ plaques from the brain. 
Another hypothesis linking apoE with AD is the direct interaction between apoE and tau protein. 
ApoE has been located in NFT mediated by tau [19]. Stable complexes between the microtubule-
binding domain of tau and the LDL-receptor binding domain of apoE3, but not apoE4, have been 
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shown in vitro [29]. Overexpression of human apoE4 in neurons of transgenic mice caused an 
increase in tau hyperphosphorylation mediated by Erk activation [30, 31]. Moreover, apoE-deficient 
mice show increased hyperphosphorylation of tau than control mice [32], which might indicate that 
apoE3 protects tau from hyperphosphorylation. A more recent study using P301S tau mutant 
transgenic mice on an apoE knock-out or knock-in background showed that apoE4 expression caused 
more brain atrophy and neurodegeneration than apoE2 or apoE3, while apoE knock-out mice were 
protected from these changes [33]. This paper also identified a role for microglia in relation to tau, 
finding that the presence of the apoE4 background promoted microglial reactivity after 
lipopolysaccharide treatment [33].  
ApoE is proteolytically cleaved in the brain 
Apolipoprotein E has been shown to be proteolytically cleaved in the human brain generating 
truncated fragments. Unfortunately, not much is known regarding fragmentation of apoE2, and reports 
on the mechanism of generation and the function of the fragments are inconsistent in the literature.  
However it is evident that the apoE fragmentation pattern differs between the apoE3 and apoE4 
isoforms [34], therefore understanding the function of the apoE fragments may be critical to 
understanding the role of apoE in AD. There is a 50% reduction of the 25 kDa N-terminal fragment in 
apoE4 compared to apoE3 brains [34]. When apoE3 or apoE4 was overexpressed specifically in either 
neurons or astrocytes, there was no fragmentation of apoE when overexpressed in astrocytes and in 
neurons there were fewer fragments of apoE4 than apoE3 [35]. This paper also identified that 
fragmentation was specific to brain regions highly affected in AD, such as the neocortex or 
hippocampus [35]. Although astrocytes are responsible for high levels of apoE expression, together 
this data suggests that the enzyme responsible for fragmentation is specifically expressed by neurons 
and that the fragments may have a role in disease onset or progression.  
A number of enzymes have been proposed to be responsible for apoE fragmentation in different 
studies (Table 1). Enzymes belonging to either the aspartic or the serine protease family have taken 
most of the attention. The first study by Marques et al. showed that the serine protease, thrombin, 
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generated a 22 kDa N-terminal apoE fragment that was neurotoxic to primary neurons [36]. 
Moreover, the 22 kDa fragment from the apoE4 isoform showed higher toxicity than the apoE3 
fragment [37, 38]. However, the apoE fragmentation pattern generated in vitro by thrombin digestion 
is different from the pattern observed in the human brain [34]. Cathepsin D, an aspartic protease, was 
proposed by Zhou et al. to generate a 24 kDa apoE fragment that does correspond to the 
fragmentation observed in the brain [39]. The apoE fragments and cathepsin D also colocalize with 
the Aβ plaques and NFTs in post mortem human tissue [39]. A chymotrypsin-like serine protease was 
proposed by Harris et al., supported by studies using the specific enzyme inhibitor α1-
antichymotrypsin [40, 41]. It was also shown that the C-terminal fragment of apoE4 formed with the 
chymotrypsin-like protease, comprising amino acids 272-299, induces neuropathology and 
behavioural deficits in transgenic mice overexpressing the fragment [40]. Most recently, high-
temperature requirement serine protease A1 (HtrA1) was shown to induce fragmentation of apoE in 
vitro, generating a fragment of 25 kDa, encompassing amino acids 1-195. HtrA1 was able to cleave 
apoE4 faster and to a greater extent than apoE3 [42]. Of particular interest, recombinant HtrA1 
generated apoE3 fragments, particularly a stable 25 kDa fragment [42], that is very similar to the 
major apoE fragment detected in the human brain [34]. Moreover, inducing apoE expression in SK-N-
SH neuroblastoma cells with all-trans retinoic acid led to the formation of a 25 kDa N-terminal apoE 
fragment, the formation of which was blocked by either HTRA1 knock-down or inhibition with the 
specific HtrA1 boronic acid inhibitor [43]. These last two papers together suggest that HtrA1 
expressed by neurons could be responsible for generating the 25 kDa N-terminal apoE fragment.  
Table 1. Enzymes proposed to cleave apolipoprotein E. 
 Enzyme proposed Fragment generated 
Marques et al., 1996 [36] Thrombin ApoE 22 kDa N-terminal 
Zhou et al., 2006 [39] Cathepsin D ApoE 24 kDa N-terminal 
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Harris et al., 2003 [40] 
Tamboli et al., 2014 [41] 
Chymotrypsin-like protease ApoE 272-299 C-terminal 
Chu et al., 2016 [42] 
Muñoz et al., 2018 [43] 
HtrA1 ApoE 25 kDa N-terminal 
 
Some studies have shown a brain homogenate pattern composed of one fragment detected at ~23-25 
kDa and a smaller fragment detected at ~10 kDa [44]. The hinge region of apoE (that connects the N-
terminal and C-terminal regions) is highly exposed, thus it is a likely potential target of enzyme 
cleavage. Moreover, apoE4 has been shown to form a molten globule, in which the N-terminal region 
is more open, and therefore more accessible to be cleaved by enzymes [45]. Predicted cleavage sites 
for cathepsin D, chymotrypsin-like protease and HtrA1 are located throughout the amino acid 
sequence of the protein, and specifically in the hinge region. These data also support the pattern seen 
in the human brain, as the predicted molecular weight of the N-terminal domain is ~24 kDa and the C-
terminal domain is ~10 kDa. Small variations in apoE molecular weight in different studies could be 
due to a carbohydrate molecule attached to Thr
194
 via O-linked glycosylation [46]. 
Understanding the function of apoE fragments 
The difference in the apoE fragmentation pattern observed in apoE3 and apoE4 brains leads us to 
question the biological roles of the different apoE fragments and whether they have a relationship 
with AD pathogenesis (Table 2). Specific apoE fragments have been directly linked with the 
formation of Aβ plaques or NFT or the initiation of neurodegeneration [35, 40, 47–49].  An 18 kDa 
N-terminal fragment (1-172 aa) of apoE4 was found within NFT of AD patients [50], however the 
presence of this fragment in cerebrospinal fluid or plasma did not correlate with AD or APOE 
genotype [51]. Huang et al. found a different fragment, 1-271 aa of apoE4, to be part of NFT-like 
inclusions in neuronal cells [48]. Moreover, there was reduced truncation of apoE3 compared to 
apoE4 and the inclusions did not occur in non-neuronal cells [48]. The same group generated a 
transgenic mouse overexpressing the fragment 1-271 of apoE4. The mice that expressed high levels of 
the fragment died at 2-4 months of age, showing AD-like neurodegeneration in the cortex and 
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hippocampus. Meanwhile, the mice that expressed lower levels of the fragment showed impaired 
learning and memory at 6-7 months of age [40]. Transgenic mice hAPPFAD [52] overexpressing apoE3 
or apoE4 showed a decrease in Aβ deposition and increase of Aβ clearance compared to mice that did 
not overexpress human apoE. However, the overexpression of the apoE4 1-271 fragment resulted in 
lower binding to Aβ peptides than apoE3 or apoE4, suggesting there was a decrease in Aβ clearance 
and an increase in Aβ deposition [53]. A similar fragment size was also tested in Neuro-2a mouse 
neuroblastoma cells, showing that the 1-272 apoE4 fragment (including both LDL-receptor binding 
and lipid binding regions) induced neurotoxicity and mitochondrial dysfunction, whereas the 1-240 
fragment of apoE4 (containing only the LDL-receptor biding region) or full-length apoE4 did not 
[54]. However, the 214-272 fragment of apoE4 (containing only the lipid-binding region) did not 
induce neurotoxicity; this data therefore suggests a requirement for both regions of apoE4 to cause 
mitochondrial dysfunction and neurotoxicity [54]. 
Other research groups have used mimetic peptides to address the function of specific fragments. The 
apoE fragment 141-155 was shown to cause specific degeneration of neurites in embryonic chick 
sympathetic neurons [55], whereas a shorter fragment, apoE 141-149, showed inhibition in 
proliferation and cytotoxicity in IL2-dependent T lymphocytes [56]. Another peptide, apoE 133-149, 
corresponding with the LDL-receptor binding region, was shown to be responsible for reducing 
inflammation after injury. The peptide was able to mimic the effects of the full-length protein, 
suppressing microglial activation and release of tumor necrosis factor-α and nitric oxide after 
lipopolysachharide administration in BV2 mouse microglial cells [57, 58]. The same 133-149 apoE 
peptide showed a neuroprotective function after exposure to N-methyl-D-aspartate, suppressing cell 
death and calcium influx in primary neuronal-glia mixed cultures from brain cortices of fetal rats [59]. 
From the same group, the peptide was studied in mouse models of other disease models, including 
multiple sclerosis and post-ischemia necrosis and also led to an improvement after administration of 
the 133-149 apoE peptide [60, 61]. Another group used the same peptide apoE 133-149 to understand 
its interaction with neuronal nicotinic acetylcholine receptors (nAChRs) [62–64]. There was a 
complete inhibition of acetylcholine-evoked responses in rat hippocampal slices when the peptide was 
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added. Furthermore, the same effect was seen when using the shorter peptide apoE 141-148, but not 
with 133-140, demonstrating that the interaction with nAChR is mediated by the arginine-rich domain 
[64]. Further studies in Xenopus laevis oocytes showed that the interaction of the apoE 133-149 
peptide, or the shorter 141-148, disrupted nAChR signaling by blocking the α7 nAChRs [62, 63]. 
Isoform-specific proteolysis has been identified in a number of different studies, showing higher 
levels of fragmentation of apoE4 compared to apoE3. A study in Neuro2a mouse neuroblastoma cells 
identified an intracellular apoE C-terminal 13 kDa fragment following transfection with the human 
apoE3 or apoE4. This fragment, that was highly expressed in apoE4-transfected cells, inhibited the 
formation of Aβ fibrils and stabilized the formation of Aβ hexamers in vitro [65].  Other studies have 
focused on the role of different N-terminal apoE4 fragments ranging from 17 to 22 kDa. Love et al. 
suggested the extracellular proteases collagenase and matrix metalloprotease-9 produce a 17 kDa 
apoE 1-151 fragment and in the apoE4 background the fragment traffics to the nucleus of BV2 mouse 
microglial cells increasing cell death [49]. Dafnis et al. showed in the SK-N-SH human 
neuroblastoma cell line that the 19 kDa N-terminal fragment of apoE4 (apoE 1-165) stimulated the 
intracellular accumulation of Aβ42, generating ROS, but this effect was absent with apoE3 or with the 
21 kDa fragment (apoE 1-185) [66, 67]. However, the 1-185 fragment of apoE4 promotes matrix 
metalloprotease 9 / tissue inhibitor of metalloprotease 1 (MMP-9/TIMP1), induced by expression of 
IL-1β in human neuroblastoma SK-N-SH cells and astrocytoma cells SW-1783 cells [68]. The 22 kDa 
fragment proposed to be generated by thrombin cleavage exhibited neurotoxicity from apoE4 but not 
when generated from apoE3 in primary neurons [36]. The same fragment was studied in embryonic 
chick sympathetic ganglia and embryonic rat hippocampus tissue showing that the fragment generated 
an increase in intracellular calcium and the neurotoxic function of the apoE4 fragment was mediated 
through the heparan sulfate proteoglycan-LDL receptor-related protein complex [37, 38]. We recently 
identified that the 25 kDa fragment generated by HtrA1 cleavage in the apoE3 background of SK-N-
SH human neuroblastoma cells was stable and induced neuritogenesis [43]. This suggests that the 25 
kDa apoE fragment may also promote neurite outgrowth in vivo. Thus, the reduction of this 25 kDa 
N-terminal fragment in apoE4 subjects could contribute to a reduction in neuritogenesis, in addition to 
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the potential neurotoxic effects previously proposed for the apoE4 C-terminal fragments along with 
other apoE peptides (Table 2). 
Table 2. Proposed functions of apolipoprotein E fragments in cell and animal models related to AD and 
differences in apoE isoforms. 
 
ApoE fragment 
studied 
Function of the 
peptide 
Model of study 
Differences within 
apoE isoforms 
Crutcher et al., 
1994 [55] 
ApoE 141-155 
Causes neurite 
degeneration 
Embryonic chick 
sympathetic ganglia 
in vitro 
N/A 
Clay et al., 1995 
[56] 
ApoE 141-149  
Exhibits 
cytotoxicity 
IL2-dependent T 
lymphocytes 
N/A 
Marques et al., 
1996 [36] 
ApoE 22 kDa  
N-terminal 
Exhibits 
cytotoxicity, 
increased in apoE4 
background 
compared to apoE3 
Primary neurons 
ApoE4 fragment 
has higher toxicity 
than apoE3 
Tolar et al., 1997 
[37] 
ApoE 22 kDa  
N-terminal 
The neurotoxic 
function of the 
fragment is 
receptor-mediated 
Embryonic chick 
sympathetic ganglia 
in vitro and 
embryonic rat 
hippocampal tissue  
ApoE4 fragment 
showed higher 
toxicity than apoE3 
Tolar et al., 1999 
[38] 
ApoE 22 kDa  
N-terminal 
Induces calcium 
influx and 
neurotoxicity 
involving cell 
surface receptors 
Embryonic chick 
sympathetic ganglia 
in vitro and 
embryonic rat 
hippocampal tissue 
Only apoE4 studied 
Huang et al., 2001 
[48] 
ApoE 1-271 
N-terminal 
Induces NFT-like 
inclusion in 
neuronal cells 
Neuro-2a mouse 
neuroblastoma cells 
ApoE4 showed 
more inclusions 
than apoE3 
Laskowitz et al., 
2001 [57] 
ApoE 133-149 
Suppresses 
microglial 
activation and 
release of TNFα 
and NO 
BV2 mouse 
microglia cells 
N/A 
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Aono et al., 2003 
[59] 
ApoE 133-149 
Suppresses 
neuronal cell death 
and calcium influx 
associated with N-
methyl-D-aspartate 
Primary neuronal-
glia cells 
N/A 
Harris et al., 2003 
[40] 
ApoE 1-271 
N-terminal 
Causes AD-like 
neurodegeneration 
and behavioural 
deficits 
Transgenic mice 
C57BL6/J 
overexpressing  
apoE 1-271 
Only apoE4 studied 
Lynch et al., 2003 
[58] 
ApoE 133-149 
Supresses 
inflammatory 
response after LPS 
administration 
Wild-type mice 
C57BL6/J 
N/A 
Klein and Yakel, 
2004 [64] 
ApoE 133-149 
ApoE 141-148 
Inhibit Ach-evoked 
responses in a dose-
dependent manner  
Rat hippocampal 
slices 
N/A 
Chang et al., 2005 
[54] 
ApoE 1-272 
N-terminal 
Exhibits 
neurotoxicity via 
mitochondrial 
dysfunction  
Neuro-2a mouse 
neuroblastoma cells 
Only apoE4 studied 
Wellnitz et al., 
2005 [65] 
ApoE 13 kDa 
C-terminal 
Inhibits Aβ fibril 
formation and 
induces formation 
and stabilization of 
hexameric species 
of Aβ 
Neuro-2a mouse 
neuroblastoma cells 
ApoE4 generates 
more 13 kDa 
fragment than 
apoE2 or 3 
Gay et al., 2006, 
2007 [62, 63] 
ApoE 133-149 
ApoE 141-148 
Block α7 nAChRs 
disrupting nAChR 
signalling 
Xenopus laevis 
oocytes  
N/A 
Dafnis et al., 2010, 
2016 [66, 67] 
ApoE 1-165  
19 kDa and apoE  
1-185 21 kDa  
N-terminal 
ApoE 1-165 
stimulates the 
intracellular 
accumulation of 
Aβ42 that generates 
ROS, but apoE  
1-185 do not 
SK-N-SH human 
neuroblastoma 
Effects not seen in 
apoE3 
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Conclusions 
Since the APOE ɛ4 allele is the major genetic risk factor for AD, understanding its role in the 
development of AD is paramount. A direct link between apoE and the two major hallmarks of the 
disease, Aβ plaques and NFTs, has been identified but the precise roles that apoE plays in AD are still 
debated. ApoE is expressed in the brain mainly by astrocytes, however the evidence suggests that 
neurons rather than astrocytes express the enzymes leading to apoE fragmentation. A number of 
enzymes have been proposed to cleave apoE, whilst different fragments have been shown to have 
diverse effects on cells. The majority of studies have focused on the toxic impact of apoE4 (reviewed 
[69]) promoting neurotoxicity [36], mitochondrial dysfunction [54], NFT-like inclusions [48], 
neurodegeneration [40], cell death [49] or suppressing microglial activation [57] (Fig. 2). However, 
our recent study has found a protective function of the apoE 25 kDa fragment that is more prevalent in 
apoE3 than apoE4 brains [43]. This suggests that in addition to the neurotoxic effects of apoE4 
fragments, a loss of neuroprotective apoE3 fragments may also contribute to neurodegeneration in 
Bien-Ly et al., 
2011 [53] 
ApoE 1-271 
N-terminal 
Decreases Aβ 
clearance and 
increases Aβ 
deposition 
Transgenic mice 
J20 line of hAPPFAD 
and overexpressing 
apoE 1-271 
Full-length apoE3 
and apoE4 
expressing mice 
were able to 
stimulate Aβ 
clearance  
Dafnis et al., 2012 
[68] 
ApoE 1-185 
21 kDa N-terminal 
Promotes 
MMP9/TIMP1 
imbalance by 
inducing IL-1β and 
reducing IL-10 
expression 
SK-N-SH human 
neuroblastoma and 
SW-1783 human 
astrocytoma cells 
Only apoE4 studied 
Love et al., 2017 
[49] 
ApoE 1-151 
17 kDa N-terminal 
Trafficking to the 
nucleus and 
increase in cell 
death 
BV2 mouse 
microglia cells 
Effects not seen in 
apoE3 
Muñoz et al., 2018 
[43] 
ApoE 1-195 
25 kDa N-terminal 
Promotes 
neuritogenesis 
SK-N-SH / SH-
SY5Y human 
neuroblastoma cells 
Only apoE3 studied 
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AD. Future studies need to address the role of apoE fragments in astrocytes, microglia and other non-
neuronal cell types and their precise role in AD pathogenesis. Very little is known about the 
fragmentation of apoE2 and this should be investigated in the future. Understanding the differences 
between apoE isoforms in different cell types will undoubtedly involve the use of induced pluripotent 
stem cells (iPSCs) that express physiological levels of endogenous genes, rather than relying on 
overexpression models. In particular the use of genome-edited isogenic lines [70] bearing 
apoE2/apoE3/apoE4 can delineate the specific effects of endogenous levels of apoE fragments from 
each genotype and their role in AD pathogenesis. 
 
Figure legends 
Fig. 1 Structure of apolipoprotein E. The N-terminal domain (1-167 aa) is connected by a hinge 
region with the C-terminal domain (206-299 aa). The LDL-receptor binding (135-150 aa) and the 
lipid binding (244-272) regions are shown. Positions 112 and 158 show the different amino acids that 
give rise to each of the apoE isoforms (ɛ2, ɛ3 and ɛ4). 
 
Fig. 2 Overview of apoE structure and the function assigned to each of the fragments studied. 
Red fragment, apoE4; blue fragment, apoE3; black fragment, N/A. 
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